Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Fauci and Panel Discuss Ongoing Challenges of the COVID-19 Pandemic, and Lessons Learned
Coronavirus disease 2019 (COVID-19) is unlike any pandemic the world has experienced in the last 100 years, said Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, during his keynote.
Addressing the QOL Impact and Disease Burden on the Families of Adolescents With Atopic Dermatitis
Atopic dermatitis (AD) has a negative impact on quality of life, and the burden of this disease in adolescents and their parents should be taken into account as part of the management of AD.
Addressing Cancer Disparities Requires Asking Questions and Putting Aside Assumptions
Speakers at Patient-Centered Oncology Care® highlighted injustices in the US health care system, the risk of financial toxicity, and how providers can do a better job to ensure their patients achieve health equity, during a panel discussion.
Pediatric Asthma Health Care Utilization Following Onset of COVID-19 Pandemic
Following the onset of the coronavirus disease 2019 (COVID-19) pandemic, changes in pediatric asthma health care delivery patterns resulted in reduced hospital admissions and systemic steroid prescriptions in Philadelphia.
Comparing Disease Impact and Activity in Psoriatic Arthritis by Ethnic Background
Patients of South Asian origins who have psoriatic arthritis have a worse clinical phenotype and worse disease impact than patients of North European origins, according to research published in Rheumatology.
Real-World Study: Dupilumab for Atopic Dermatitis More Effective Than Clinical Trial Results
The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.
Precision Medicine Could Yield Significant Cost Savings in RA Treatment
A decision-analytic model could save more than $7 million in overall ineffective health care costs per 1000 patients by predicting which patients with rheumatoid arthritis (RA) will have an inadequate response to anti–tumor necrosis factor therapies.
Improved Treatment Options for SMA Present New Opportunities, Challenges
There are now multiple therapeutic options available for spinal muscular atrophy (SMA), a disease once considered incurable; however, there remains a need for additional treatments and better ways to predict treatment response.